Department of Pharmaceutical Sciences, Chicago College of Pharmacy, Midwestern University, Downers Grove, IL 60515, USA.
Eur J Pharmacol. 2010 Jun 10;635(1-3):62-71. doi: 10.1016/j.ejphar.2010.03.003. Epub 2010 Mar 19.
We have previously shown the involvement of central endothelin (ET) mechanisms in morphine analgesia and tolerance. Here we investigated the interaction of centrally administered endothelin ET(A) receptor antagonist, BMS182874, with DAMGO (micro opioid receptor agonist), SNC80 (delta opioid receptor agonist), U50,488H (kappa opioid receptor agonist), and oxycodone (micro and kappa opioid receptor agonist) towards antinociception, tolerance to antinociception and body temperature. Antinociception was determined using tail-flick latency method. BMS182874 (50microg, i.c.v.) treatment alone did not produce analgesia or change in body temperature. However, BMS182874 significantly enhanced antinociception response of DAMGO (66.75%), SNC80 (62.40%), U50,488H (55.38%), and oxycodone (61.72%). Chronic treatment with DAMGO, SNC80, U50,488H or oxycodone, induced tolerance to antinociception. Treatment with BMS182874 restored antinociceptive effect in mice that were tolerant to DAMGO, SNC80, U50,488H as well as oxycodone. Antinociceptive response of DAMGO, SNC80, U50,488H, and oxycodone in tolerant mice treated with BMS182874 was significantly higher (44.55%, 37.48%, 43.02%, and 56.08%, respectively) compared to tolerant mice treated with vehicle. Body temperature decreased with DAMGO, SNC80, U50,488H, and oxycodone; tolerance did not develop to hypothermic effect and BMS182874 did not affect DAMGO, SNC80, U50,488H, or oxycodone induced changes in body temperature. Opioid-antagonist naloxone, completely blocked antinociceptive effect of DAMGO, SNC80, U50,488H or oxycodone and potentiation of antinociception by BMS182874. It is concluded that BMS182874 potentiated antinociception and restored antinociceptive effect in mice tolerant to micro, delta and kappa selective, as well as a non-selective opioid receptor agonist. Therefore, endothelin ET(A) receptor antagonists could be useful in the restoration of antinociceptive effect during tolerance to opiates.
我们之前已经证明了中枢内皮素(ET)机制在吗啡镇痛和耐受中的作用。在这里,我们研究了中枢给予内皮素 ET(A)受体拮抗剂 BMS182874 与 DAMGO(微阿片受体激动剂)、SNC80(德尔塔阿片受体激动剂)、U50,488H(κ阿片受体激动剂)和奥昔康定(微阿片受体和κ阿片受体激动剂)对镇痛、镇痛耐受和体温的相互作用。使用尾巴闪烁潜伏期方法确定镇痛作用。BMS182874(50μg,icv)单独治疗不会产生镇痛作用或改变体温。然而,BMS182874 显著增强了 DAMGO(66.75%)、SNC80(62.40%)、U50,488H(55.38%)和奥昔康定(61.72%)的镇痛反应。慢性给予 DAMGO、SNC80、U50,488H 或奥昔康定可诱导镇痛耐受。BMS182874 治疗可恢复对 DAMGO、SNC80、U50,488H 以及奥昔康定耐受的小鼠的镇痛作用。在接受 BMS182874 治疗的耐受小鼠中,DAMGO、SNC80、U50,488H 和奥昔康定的镇痛反应显著更高(分别为 44.55%、37.48%、43.02%和 56.08%)与接受载体治疗的耐受小鼠相比。DAMGO、SNC80、U50,488H 和奥昔康定可降低体温;对体温过低作用没有产生耐受性,BMS182874 不影响 DAMGO、SNC80、U50,488H 或奥昔康定引起的体温变化。阿片受体拮抗剂纳洛酮完全阻断了 DAMGO、SNC80、U50,488H 或奥昔康定的镇痛作用,以及 BMS182874 对镇痛作用的增强。结论:BMS182874 增强了对微阿片受体、德尔塔阿片受体和κ阿片受体以及非选择性阿片受体激动剂的镇痛作用,并恢复了对这些激动剂耐受的小鼠的镇痛作用。因此,内皮素 ET(A)受体拮抗剂可用于恢复阿片类药物耐受期间的镇痛作用。